PMID- 30584024
OWN - NLM
STAT- MEDLINE
DCOM- 20200603
LR  - 20200603
IS  - 2152-2669 (Electronic)
IS  - 2152-2650 (Print)
IS  - 2152-2669 (Linking)
VI  - 19
IP  - 3
DP  - 2019 Mar
TI  - Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients 
      With Non-Hodgkin Lymphomas.
PG  - 135-141
LID - S2152-2650(18)31465-4 [pii]
LID - 10.1016/j.clml.2018.11.021 [doi]
AB  - INTRODUCTION: Copanlisib is a phosphoinositol 3-kinase (PI3K) inhibitor approved 
      for the third-line treatment of follicular non-Hodgkin lymphoma. Although the 
      drug is generally well-tolerated, it can be associated with several unique and 
      potentially serious adverse effects (AEs). Two of the most common toxicities not 
      seen with other PI3K inhibitors include hyperglycemia and hypertension, which 
      primarily occur during infusion and resolve shortly thereafter, and likely relate 
      to targeting the PI3K alpha isoform. Other toxicities less commonly observed with 
      copanlisib than with other approved drugs in this class include non-infectious 
      pneumonitis, infections, diarrhea and colitis, and hepatobiliary toxicity. 
      MATERIALS AND METHODS: A panel composed of experts in lymphoma, diabetes, and 
      hypertension convened to develop guidance pertaining to the administration of 
      copanlisib and the management of the AEs associated with copanlisib treatment. 
      RESULTS: Recommendations were formulated pertaining to the management of AEs 
      associated with copanlisib treatment, particularly infusion-related hyperglycemia 
      and hypertension, noninfectious pneumonitis, infections, diarrhea, and colitis. 
      The recommendations herein reflect the consensus of the members of this panel, 
      all of whom contributed to these suggested approaches to patient supportive care. 
      CONCLUSION: There are a number of challenges associated with the use of 
      copanlisib. Infusion-related hypertension and hyperglycemia occur frequently, 
      although they are transient, reversible, and rarely of clinical significance; 
      this report provides guidance as to their management.
CI  - Copyright (c) 2018 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Cheson, Bruce D
AU  - Cheson BD
AD  - Department of Internal Medicine, Division of Hematology-Oncology, Georgetown 
      Lombardi Comprehensive Cancer Center, Washington, DC. Electronic address: 
      bdc4@georgetown.edu.
FAU - O'Brien, Susan
AU  - O'Brien S
AD  - Department of Medicine, University of California, Irvine, CA.
FAU - Ewer, Michael S
AU  - Ewer MS
AD  - Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, 
      TX.
FAU - Goncalves, Marcus D
AU  - Goncalves MD
AD  - Department of Endocrinology, Weill Cornell Medical Center, New York, NY.
FAU - Farooki, Azeez
AU  - Farooki A
AD  - Department of Endocrinology, Memorial Sloan Kettering Cancer Center, New York, 
      NY.
FAU - Lenz, Georg
AU  - Lenz G
AD  - Department of Hematology, Oncology and Pneumology, Universitat Munster, Munster, 
      Germany.
FAU - Yu, Anthony
AU  - Yu A
AD  - Department of Cardiology, Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Fisher, Richard I
AU  - Fisher RI
AD  - Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA.
FAU - Zinzani, Pierre L
AU  - Zinzani PL
AD  - Department of Experimental, Diagnostic and Specialty Medicine, University of 
      Bologna, Bologna, Italy.
FAU - Dreyling, Martin
AU  - Dreyling M
AD  - Department of Internal Medicine, University of Munich, Munich, Germany.
LA  - eng
GR  - K23 CA218897/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20181129
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Pyrimidines)
RN  - 0 (Quinazolines)
RN  - WI6V529FZ9 (copanlisib)
SB  - IM
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Drug-Related Side Effects and Adverse Reactions/*therapy
MH  - Humans
MH  - Lymphoma, Non-Hodgkin/*drug therapy
MH  - Pyrimidines/*adverse effects/pharmacology/therapeutic use
MH  - Quinazolines/*adverse effects/pharmacology/therapeutic use
PMC - PMC6642803
MID - NIHMS1038643
OTO - NOTNLM
OT  - Copanlisib
OT  - Follicular lymphoma
OT  - Hyperglycemia
OT  - Hypertension
OT  - PI3K
EDAT- 2018/12/26 06:00
MHDA- 2020/06/04 06:00
PMCR- 2020/03/01
CRDT- 2018/12/26 06:00
PHST- 2018/10/11 00:00 [received]
PHST- 2018/11/22 00:00 [accepted]
PHST- 2018/12/26 06:00 [pubmed]
PHST- 2020/06/04 06:00 [medline]
PHST- 2018/12/26 06:00 [entrez]
PHST- 2020/03/01 00:00 [pmc-release]
AID - S2152-2650(18)31465-4 [pii]
AID - 10.1016/j.clml.2018.11.021 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):135-141. doi: 
      10.1016/j.clml.2018.11.021. Epub 2018 Nov 29.